Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNFDYE)

• Drug Name: KD3010 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metabolic disorder	5C50-5D2Z	Phase 1	[1]
Obesity	5B81	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 75412604
  TTD Drug ID: DMNFDYE

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor delta (PPARD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[2]
MBX-8025	DMNTCV4	Obesity	5B81	Phase 2/3	[3]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[4]
T3D-959	DMR3245	Alzheimer disease	8A20	Phase 2	[5]
SAR351034	DM15PG9	Dyslipidemia	5C80-5C81	Phase 1	[6]
CER-002	DMLBKZV	Dyslipidemia	5C80-5C81	Phase 1	[7]
PMID25416646-Compound-Figure5-C	DM17FKL	N. A.	N. A.	Patented	[8]
GW-501516	DMPL2KM	Type-1 diabetes	5A10	Discontinued in Phase 4	[9]
Sodelglitazar	DMJ816F	Hyperlipidaemia	5C80	Discontinued in Phase 2	[10]
Indeglitazar	DMS56UD	Type-2 diabetes	5A11	Discontinued in Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor delta (PPARD)	TT2JWF6	PPARD_HUMAN	Agonist	[1]

References

• [1] Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
• [2] Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
• [3] ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
• [4] Phrma report (2013 Alzheimers disease)
• [5] T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
• [6] Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
• [7] Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
• [8] PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
• [9] Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
• [10] Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
• [11] Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.